We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lagevrio

News List

Oral COVID-19 antivirals market set for growth CPhIonline
January 13, 2022
Lagevrio and Paxlovid are the only COVID-19 pills cleared for emergency use at present, but others are coming with developers racing to bring oral antivirals to this potentially lucrative market.
EMA issues advice on use of Lagevrio for the treatment of COVID-19 EuropeanPharmaceuticalReview
November 25, 2021
The European Medicines Agency (EMA)’s human medicine committee, the Committee for Medicinal Products for Human Use (CHMP), has issued advice on the use of Lagevrio...
EMA CHMP issues advice on usage of Merck-Ridgeback’s Covid-19 medicine Pharmaceutical-Technology
November 23, 2021
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued advice on the usage of Merck Sharp & Dohme and Ridgeback Biotherapeutics’ Lagevrio (molnupiravir/ MK 4482) to treat Covid-19.